Boxer Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$25.2M Buy
283,054
+183,054
+183% +$17.6M 2.19% 13
2026
Q2
$8.88M Buy
+100,000
New +$7.3M 0.67% 27
2025
Q1
– Sell
-466,680
Closed -$10.9M – 55
2024
Q4
$10.9M Buy
+466,680
New +$13.7M 0.93% 30

Other funds holding SYRE

Boxer Capital Management's SYRE Position: Q3 2026 in Review

Boxer Capital Management increased its Spyre Therapeutics (SYRE) stake by 183% in Q3 2026, buying an estimated $17.6M and bringing the position to 283,054 shares worth $25.2M. The position accounts for 2.19% of the portfolio, ranked #13.

Boxer Capital Management first reported a position in SYRE in Q4 2024 and has held it in 3 quarters since. 286 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Boxer Capital Management held 283,054 shares of Spyre Therapeutics worth $25.2M as of Q3 2026.
  • Boxer Capital Management bought 183,054 Spyre Therapeutics shares in Q3 2026, an estimated $17.6M.
  • Spyre Therapeutics made up 2.19% of Boxer Capital Management's portfolio in Q3 2026, its #13 holding.
  • Boxer Capital Management first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 286 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Boxer Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.